WHO reports fewer tuberculosis cases and deaths

The World Health Organization says domestic tuberculosis funding rose 14% to US$ 5.6 billion between 2024 and 2025, partly offsetting a similar decline in international financing.
In this article
Sole source: Fewer people are developing and dying from tuberculosis, the World Health Organization (WHO) says in its Global Tuberculosis Report 2026, released on 12 November 2026. WHO estimates that 10.6 million people developed the disease in 2025 and 1.1 million died from it.
In its announcement, WHO said domestic investment helps sustain tuberculosis services amid pressure on international funding. Its director-general, Tedros Adhanom Ghebreyesus, described the disease as preventable and treatable.
Progress falls short of incidence target
WHO says tuberculosis deaths have fallen 35% since 2015, reaching the first mortality milestone of its End TB Strategy five years later than planned. It estimates that treatment has saved 86 million lives since 2000.
The global incidence rate—the number of new cases per 100,000 people—fell 14% since 2015, short of the 50% reduction milestone for 2025. WHO says tuberculosis remains the leading cause of death from a single infectious agent.
WHO says 30 countries accounted for 88% of people who developed tuberculosis in 2025. Changes in incidence varied across its regions:
| WHO region | Change |
|---|---|
| Europe | Fell 42% |
| Africa | Fell 30% |
| South-East Asia | Fell 18% |
| Eastern Mediterranean | Fell 6.6% |
| Western Pacific | 0% |
| Americas | Rose 13% |
Incidence in the Americas rose for the fifth consecutive year in 2025. WHO attributes regional differences to factors including health-system strength, access to services, risk factors and sustained investment.
Gaps in diagnosis and treatment
WHO says 8.4 million people were diagnosed with tuberculosis in 2025, leaving an estimated 2.2 million either undiagnosed or unreported. Of newly diagnosed patients, 59% received a WHO-recommended rapid diagnostic test; the target is 100% by 2027.
An estimated 370,000 people developed tuberculosis resistant to rifampicin, a drug used to treat the disease, in 2025. WHO says 42% received treatment. Among those treated, use of its recommended six-month regimen rose from 18% in 2024 to 42% in 2025.
WHO says tuberculosis research received US$ 1.2 billion in 2023, less than a quarter of the US$ 5 billion annual target for 2027. Tedros urged countries and partners to expand access to services, protect essential funding and accelerate development of new tools. WHO also calls for greater investment in vaccines, diagnostics and treatments, alongside wider access to prevention, rapid diagnosis and effective treatment.
Follow AveNews
Earlier in Science
SpaceWebb detects water and carbon dioxide ice around Beta Pictoris
Spectra from opposite sides of the young star’s debris disk show both forms of carbon dioxide ice alongside water ice; researchers say the molecules are mixed within the ice.
3 min
EarthArmenia’s Eco-Patrol Service sets up department for two provinces
The department will cover Shirak and Aragatsotn, with a base in Shirak and a planned 103 officers. Recruitment competitions have already been announced.
1 min
HealthEngland records 419 GLP-1 drug prescriptions for children in 2025–26
A further 341 prescriptions were issued to under-18s from April to July 2026. The figures cover community dispensing, leaving hospital and private treatment outside the count.
3 min
